- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
- MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
- MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
- MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
- MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
- MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
- MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
More ▼
Key statistics
On Monday, MaxCyte Inc (MXCT:NSQ) closed at 4.71, -15.06% below its 52-week high of 5.55, set on Jan 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.74 |
---|---|
High | 4.82 |
Low | 4.68 |
Bid | -- |
Offer | 4.94 |
Previous close | 4.71 |
Average volume | 712.30k |
---|---|
Shares outstanding | 104.54m |
Free float | 98.05m |
P/E (TTM) | -- |
Market cap | 410.86m USD |
EPS (TTM) | -0.3675 USD |
Data delayed at least 15 minutes, as of May 13 2024 21:00 BST.
More ▼